News

Scottish Medicines Consortium says ‘no’ to use of Imnovid® in Scotland

The Scottish Medicines Consortium (SMC) has issued guidance not to recommend Imnovid (pomalidomide) in combination with low-dose dexamethasone for use in relapsed and refractory myeloma patients who have received prior treatment with Velcade® and Revlimid® and have demonstrated disease progression on their last treatment. Although the SMC acknowledged that pomalidomide was clinically significant in this patient group,…

Details

KRN5500 granted orphan drug designation for the treatment of myeloma

DARA Biosciences Inc., an American pharmaceutical company, has announced that the FDA has granted Orphan Drug Designation for its investigational drug KRN5500 for the treatment of myeloma. KRN5500 is a novel, intravenous, non-opioid, non-narcotic compound currently being developed for the parenteral treatment of painful, chronic, chemotherapy-induced peripheral neuropathy. Pre-clinical studies show that KRN5500, a spicimycin…

Details

Panobinostat submitted to the FDA for approval as a new treatment for myeloma

Novartis, the Swiss pharmaceutical company, has announced that the US Food and Drug Administration (FDA) has granted priority review for its licensing application of panobinostat, a histone deacetylase inhibitor, as a new treatment for myeloma. The submission is based on the results of the PANORAMA-1 trial involving panobinostat in combination with Velcade® and dexamethasone in…

Details

Updated UK guideline for the diagnosis and management of myeloma

The British Committee for Standards in Haematology (BCSH) and the United Kingdom Myeloma Forum (UKMF) Guideline for the Diagnosis and Management of Myeloma has recently been updated. Originally published in 2011, the latest changes to the guideline include the following recommendations: cytogenetic analysis should be performed in all patients at diagnosis; a second autologous stem…

Details

New Phase III trial of daratumumab in myeloma to commence

Genmab, the Danish biotechnology company, has announced that it’s partner Janssen Biotech Inc. will be starting a new Phase III trial of its investigational drug daratumumab in relapsed and/or refractory myeloma patients. Daratumumab is a human CD38 monoclonal antibody which has shown promising anti-myeloma activity both as a monotherapy and in combination with other anti-myeloma…

Details

Elotuzumab granted Breakthrough Therapy Designation for the treatment of myeloma

The pharmaceutical companies, Bristol-Myers Squibb and AbbVie have announced that their investigational drug elotuzumab has been granted Breakthrough Therapy Designation by the US Food and Drug Administration (FDA). Elotuzumab, a humanised anti-CS1 monoclonal antibody is being studied in various clinical trials as a potential treatment for myeloma both in the newly diagnosed and relapsed setting.…

Details